Dublin, Ireland-December 14th, 2009
ICON plc has expanded its European Central Laboratory, located in South County Business Park, Dublin. The newly-designed 41,000 sq ft (3,800m²) facility, which is three times the size of the previous laboratory, provides centralized testing and site support services to clinical investigators in over 70 countries throughout Europe, Middle East, and Africa.
The new laboratory incorporates enhanced automation which is intended to enable reductions in turn-around time for sample testing and reporting, and according to the company, has quadrupled the laboratory’s sample management and storage capacity. In addition, the larger facility has enabled the introduction of new platforms to enhance ICON’s test menu in specialized areas including microbiology, molecular diagnostics, flow cytometry, endocrinology, and RIA. New laboratories have also been created in an effort to accommodate more specialized testing services in the areas of anatomic pathology, molecular diagnostics, and multiplex assays, which will be operational in early 2010.
“Efficient sample management and reporting, and providing an extensive test menu are key fundamentals of any laboratory,” commented Peter Gray, CEO at ICON plc. “The extra capacity in our Dublin laboratory enables ICON to extend our capabilities to support clients’ demands for more sophisticated testing.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.